Skip Navigation

European Journal of Heart Failure 2002 4(6):757-763; doi:10.1016/S1388-9842(02)00113-7
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brehm, B. R.
Right arrow Articles by Risler, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brehm, B. R.
Right arrow Articles by Risler, T.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2002 European Society of Cardiology

Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study

Bernhard R. Brehm*, Sabine C. Wolf, Sandra Görner, Nina Buck-Müller and Teut Risler

Medizinische Klinik III, Otfried-Müllerstr. 10, 72076 Tübingen, Germany

* Corresponding author. Tel.: +49-7071-2982711; fax: +49-7071-360245. E-mail address: bernhard.brehm{at}onlinehome.de


   Abstract

Background: Sympathetic activity is a significant predictor of a poor prognosis in heart failure. Beta-blockers have been shown to improve the prognosis of patients with heart failure.

Aim: This pilot study examined the tolerability and efficacy of the new β-blocker nebivolol on left ventricular function in patients with chronic heart failure.

Methods and Results: Twelve patients with an ejection fraction of 13–39% were included in this double blind, placebo-controlled randomized trial of nebivolol administered in addition to standard therapy. Exercise time, heart rate, left ventricular function and tolerability were examined at baseline and after 3 months of orally administered nebivolol (2.5 and 5 mg, n=6) or placebo (n=6). Nebivolol was well tolerated and the NYHA class improved in four patients. Heart rate decreased while the maximal exercise duration and performance remained stable. Left ventricular function increased (ejection fraction 31.5±10.11 to 42.0±10.99%, P≤0.01) after 12 weeks of nebivolol. The left ventricular end-systolic diameter decreased in the nebivolol-group from 56.5±9.40 to 50.2±9.43 mm (P≤0.02).

Conclusion: These data indicate that nebivolol might improve cardiac function in patients with reduced left ventricular function.

Key Words: β-Blocker • Chronic heart failure • Left ventricular function

Received December 17, 2001; Revised March 19, 2002; Accepted May 21, 2002


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur J Heart FailHome page
J. Abdulla, L. Kober, E. Christensen, and C. Torp-Pedersen
Effect of beta-blocker therapy on functional status in patients with heart failure -- A meta-analysis
Eur J Heart Fail, August 1, 2006; 8(5): 522 - 531.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
I. Edes, Z. Gasior, and K. Wita
Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study
Eur J Heart Fail, June 1, 2005; 7(4): 631 - 639.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
J. G.F. Cleland, P. H. Loh, N. Freemantle, A. L. Clark, and A. P. Coletta
Clinical trials update from the European Society of Cardiology: SENIORS, ACES, PROVE-IT, ACTION, and the HF-ACTION trial
Eur J Heart Fail, October 1, 2004; 6(6): 787 - 791.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.